Our Publication

The Engineered Drug 3′UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer

Chidiebere U. Awah^1,2,*Joo Sun Mun³,Aloka Paragodaarachchi^3,4,Baris Boylu¹,Chika Ochu¹,Hiroshi Matsui^3,5,6 and Olorunseun O. Ogunwobi^1,2,7

Awah CU*+, Glemaud Y, Levine F, Yang K, Ansary A, Dong F, Ash L, Zhang J, Ogunwobi OO+. Destabilized 3’UTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models. 2022; bioRxiv 2022.08.14.503914; doi: https://doi.org/10.1101/2022.08.14.503914

2. ChidiebereU.Awah*,Fu Dong,Fayola Levine, Leonard Ash,Yana Glemaud,Olorunseun Ogunwobi*. Engineered destabilized AU rich elements on the 3UTR of HER2 degrades HER2, inhibits proliferation, and induces apoptosis in HER2 positive trastuzumab resistant breast cancer cells. Cancer Res (2022) 82 (12_Supplement): 1788. https://doi.org/10.1158/1538-7445.AM2022-1788

3. Chidiebere Awah*,Fu Dong,Yana Glemaud,Fayola Levine,Olorunseun Ogunwobi*. Engineered destabilized ARE on the 3UTR of MYC degrades oncogenic c-MYC transcript and protein and induces apoptosis in multiple cancer type. Cancer Res (2022) 82 (12_Supplement): 1809. https://doi.org/10.1158/1538-7445.AM2022-1809

4. Awah CU*+, Ansary A, Glemaud Y, Levine F, Ogunwobi OO⁺. Effect of Engineered Destabilized HER2 3'UTR ARE on the Proliferation of HER2+ Trastuzumab Resistant Breast Cancer Cells 2022, SPEECH Conference

5. Awah CU*+, Glemaud Y, Ansary A, Levine F, Ogunwobi OO⁺ Engineered Destabilized HER2 3'UTR ARE as Novel Therapeutics for EGFR T790M and HER2 mutated NSCLC, 2022, SPEECH Conference.

Destabilized 3’UTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models | bioRxiv

Nanocage delivered engineered destabilized HER2 3UTR ARE reduced growth of primary EGFR T790M HER2 overexpressing osimertinib and trastuzumab resistant non small cell lung cancer and inhibited liver and lung metastasis in vivo

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Matsui; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 3417.

In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Matsui; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 3900.

Targeting cMYC in metastatic castration resistant and neuroendocrine prostate cancer

Chidiebere U. Awah; Olorunseun O. Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 4504.

Nanocage delivered engineered destabilized 3UTR ARE of cMYC inhibits triple negative breast cancer growth and metastasis in vivo by targeting cMYC and downregulating STAT5A5B

Chidiebere U. Awah; Joo Sun Mun; Baris Boylu; Alooka Paragodaarachchi; Chika Ochu; Junfei Zhang; Hiroshi Mastui; Olorunseun Ogunwobi. Cancer Res (2023) 83 (7_Supplement): 1459.

Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models

Chidiebere U. Awah^1,2*, Yana Glemaud¹, Fayola Levine^1,2, Kiseok Yang¹, Afrin Ansary¹, Fu Dong¹, Leonard Ash¹, Junfei Zhang³ and Olorunseun O. Ogunwobi^1,2*

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

Chidiebere U. Awah^1,2*Joo Sun Mun³Aloka Paragodaarachchi^3,4Baris Boylu¹Martin Nzegwu⁵Hiroshi Matsui^3,4,6,7Olorunseun Ogunwobi^1,2,8*

Abstract 3039: Pan cancer therapeutic inhibition of oncogenic c-MYC by the engineered destabilized 3’UTR of c-MYC

Chidiebere U. Awah

Abstract 5590: Engineered destabilized 3’UTR of TEAD1 therapeutically inhibits and degrades TEAD1 mRNA and YAP1 interactors across multiple cancers

Chidiebere U. Awah

Gallery

Contacts

Our Publication

Our Address

Our Mailbox

Our Phone